Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?

Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.

Pharmaceutical giant Merck (MRK) is best known for its cancer blockbuster KEYTRUDA, but lately, its stock has been the main event. Shares have climbed +84% over the last twelve months, a run that has handily outpaced the S&P 500’s +19.1% gain. That performance puts Merck at the very top of its competitive class. The problem is, its underlying business results sit near the bottom.

While the company’s headline P/E of 116.7 is distorted by one-off acquisition charges and write-downs weighing on trailing GAAP earnings, even its adjusted P/E tells a demanding story. The question remains whether the market has correctly priced in a major future for Merck, or simply pushed the stock ahead of its underlying earnings power.

The Stock’s Rank Is Disconnected From Its Financials.

Among its closest rivals, Merck’s +84% one-year stock return is first in a group of six. Yet its operational metrics tell a different story. The company’s revenue grew 4.6% over the last twelve months, placing it fourth in the group and well behind the 8.1% growth at Johnson & Johnson. It’s a fraction of the 50% expansion posted by Eli Lilly.

The gap is even starker on profitability. Merck’s 10.5% operating margin ranks dead last among its peers. That figure is less than a third of Eli Lilly’s 50% margin and less than half of the 27% margin Johnson & Johnson delivered over the same period. The market is rewarding Merck with a top-tier return for bottom-tier efficiency and middle-of-the-pack growth.

The Market Is Paying For A Pipeline It Believes Is De-Risked.

The market’s enthusiasm isn’t based on last year’s results, but on the promise of the next decade. Management is pointing to a pipeline with a potential “greater than $70 billion of commercial opportunity” from over 20 new products. This is the narrative fueling the stock. Recent events have added tangible proof points, including the FDA approval for LIPFENDRA, the “first and only oral PCSK9 inhibitor” for high cholesterol.

Beyond that, the company announced positive Phase III results for its cancer therapy sac-TMT and its immunology drug tulisokibart. Investors are betting this wave of innovation will successfully navigate the eventual patent expiration of KEYTRUDA. While that patent cliff remains a critical hurdle, the bull case rests on the idea that recent clinical milestones have substantially de-risked the pipeline meant to replace it.

The strongest argument against this optimism is the immense execution risk ahead. A pipeline projected at greater than $70 billion in commercial opportunity is not the same as cash in the bank. The transition away from KEYTRUDA remains the company’s defining challenge, and launching multiple potential blockbusters simultaneously is a monumental task. While analysts have pressed management on the pace of initial access for LIPFENDRA, the broader challenge remains converting early formulary coverage into rapid adoption in a market known for its inertia.

The LIPFENDRA Launch Is The First Real Test.

The debate boils down to commercial execution. The pipeline’s potential is clear, but turning that potential into profit is where the risk lies. The first, most visible test of Merck’s ability to deliver on its post-KEYTRUDA vision is happening now with the launch of LIPFENDRA. Management’s goal extends beyond competing with existing drugs; it aims to achieve broad “market expansion” for a new class of oral therapy.

For investors, what bears watching is the early adoption and sales trajectory of LIPFENDRA. Its performance over the next several quarters will provide the first concrete data point on whether Merck can convert its pipeline promise into financial reality. It will be a powerful signal as to whether the market has this story right, or if the stock’s stellar run was premature.

This piece pulled one thread; our full peer-by-peer dashboards for MRK lay every metric side by side, updated daily.

Prefer the theme to this single name? A healthcare ETF like XLV holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.

Even The Best Of The Group Is Still One Stock

Whichever name wins a peer comparison, buying it concentrates you in one company and one industry, and industries move together: when the group catches a cold, the best house on the block still sneezes.

The Trefis High Quality (HQ) Portfolio diversifies across roughly 30 quality names in different industries, selected on fundamentals and re-balanced with discipline, so no single group’s weather decides the outcome. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the comparison to understand the stock; use the portfolio to own the market’s best.